| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ... New England Journal of Medicine 378 (5), 439-448, 2018 | 4708 | 2018 |
| Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials N Boissel, MF Auclerc, V Lhéritier, Y Perel, X Thomas, T Leblanc, ... Journal of Clinical Oncology 21 (5), 774-780, 2003 | 742 | 2003 |
| Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) C Preudhomme, C Sagot, N Boissel, JM Cayuela, I Tigaud, S de Botton, ... Blood, The Journal of the American Society of Hematology 100 (8), 2717-2723, 2002 | 618 | 2002 |
| Cooperating gene mutations in acute myeloid leukemia: a review of the literature A Renneville, C Roumier, V Biggio, O Nibourel, N Boissel, P Fenaux, ... leukemia 22 (5), 915-931, 2008 | 512 | 2008 |
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) N Boissel, H Leroy, B Brethon, N Philippe, S De Botton, A Auvrignon, ... Leukemia 20 (6), 965-970, 2006 | 451 | 2006 |
| KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, ... The Lancet 398 (10299), 491-502, 2021 | 443 | 2021 |
| Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia E Jourdan, N Boissel, S Chevret, E Delabesse, A Renneville, P Cornillet, ... Blood, The Journal of the American Society of Hematology 121 (12), 2213-2223, 2013 | 399 | 2013 |
| Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following … G Martinelli, N Boissel, P Chevallier, O Ottmann, N Gökbuget, MS Topp, ... Journal of Clinical Oncology 35 (16), 1795-1802, 2017 | 391 | 2017 |
| Rituximab in B-lineage adult acute lymphoblastic leukemia S Maury, S Chevret, X Thomas, D Heim, T Leguay, F Huguet, P Chevallier, ... New England Journal of Medicine 375 (11), 1044-1053, 2016 | 368 | 2016 |
| Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia K Beldjord, S Chevret, V Asnafi, F Huguet, ML Boulland, T Leguay, ... Blood, The Journal of the American Society of Hematology 123 (24), 3739-3749, 2014 | 349 | 2014 |
| A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission N Vey, JH Bourhis, N Boissel, D Bordessoule, T Prebet, A Charbonnier, ... Blood, The Journal of the American Society of Hematology 120 (22), 4317-4323, 2012 | 300 | 2012 |
| Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype N Boissel, A Renneville, V Biggio, N Philippe, X Thomas, JM Cayuela, ... Blood 106 (10), 3618-3620, 2005 | 298 | 2005 |
| A landscape of germ line mutations in a cohort of inherited bone marrow failure patients O Bluteau, M Sebert, T Leblanc, R Peffault de Latour, S Quentin, E Lainey, ... Blood, The Journal of the American Society of Hematology 131 (7), 717-732, 2018 | 297 | 2018 |
| Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation … M Balsat, A Renneville, X Thomas, S De Botton, D Caillot, A Marceau, ... Journal of Clinical Oncology 35 (2), 185-193, 2017 | 284 | 2017 |
| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 278 | 2020 |
| Comprehensive mutational profiling of core binding factor acute myeloid leukemia N Duployez, A Marceau-Renaut, N Boissel, A Petit, M Bucci, S Geffroy, ... Blood, The Journal of the American Society of Hematology 127 (20), 2451-2459, 2016 | 262 | 2016 |
| Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group N Boissel, O Nibourel, A Renneville, C Gardin, O Reman, N Contentin, ... Journal of Clinical Oncology 28 (23), 3717-3723, 2010 | 260 | 2010 |
| Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Heuser, Y Ofran, N Boissel, SB Mauri, C Craddock, J Janssen, ... Annals of Oncology 31 (6), 697-712, 2020 | 232 | 2020 |
| Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia C Callens, S Coulon, J Naudin, I Radford-Weiss, N Boissel, E Raffoux, ... Journal of Experimental Medicine 207 (4), 731-750, 2010 | 200 | 2010 |
| Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion E Lengline, K Beldjord, H Dombret, J Soulier, N Boissel, E Clappier Haematologica 98 (11), e146, 2013 | 199 | 2013 |
Emmanuel RAFFOUXMedical Doctor, Hopital Saint Louis, Paris在 sls.aphp.fr 的电子邮件经过验证
